Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-line treatment of advanced colorectal cancer with the aim of assessing effect on overall survival. METHODS: In this random...

Descripción completa

Detalles Bibliográficos
Autores principales: Maughan, Timothy S, Adams, Richard A, Smith, Christopher G, Meade, Angela M, Seymour, Matthew T, Wilson, Richard H, Idziaszczyk, Shelley, Harris, Rebecca, Fisher, David, Kenny, Sarah L, Kay, Edward, Mitchell, Jenna K, Madi, Ayman, Jasani, Bharat, James, Michelle D, Bridgewater, John, Kennedy, M John, Claes, Bart, Lambrechts, Diether, Kaplan, Richard, Cheadle, Jeremy P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Publishing Group 2011
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159415/
https://www.ncbi.nlm.nih.gov/pubmed/21641636
http://dx.doi.org/10.1016/S0140-6736(11)60613-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159415/
https://www.ncbi.nlm.nih.gov/pubmed/21641636
http://dx.doi.org/10.1016/S0140-6736(11)60613-2

Ejemplares similares